The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, outlines the findings of the Phase II FIL Copa-RB trial (NCT02391116) which aimed to investigate the combination therapy of copanlisib, rituximab, and bendamustine for the treatment of transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Unfortunately, due to an unfavorable safety profile and recruitment challenges due to the COVID-19 pandemic, this study was terminated prematurely, and the development of this combination in this patient population is not continuing. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Lecture Fees: Servier, Roche, Janssen, Incyte, AbbVie; Membership on an entity’s Board of Directors or advisory committees: Novartis, Gilead, Genmab, Bayer.
